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Abstract
In the Netherlands, there is no registry system regarding the livebirth prevalence of trisomy 21 (T21). In 2007, a national
screening programme was introduced for all pregnant women, which may have changed the livebirth prevalence of T21. The
aim of this study is to analyse trends in factors that inﬂuence livebirth prevalence of T21 and to estimate the livebirth
prevalence of T21 for the period of 2000–2013. National data sets were used on the following: (1) livebirths according to
maternal age and (2) prenatal testing and termination of pregnancy (ToP) following diagnosis of T21. These data are
combined in a model that uses maternal age-speciﬁc risk on T21 and correction factors for natural foetal loss to assess
livebirth prevalence of T21. The proportion of mothers aged ≥ 36 years has increased from 12.2% in 2000 to 16.6% in 2009,
to gradually decrease afterwards to 15.2% in 2013. The number of invasive tests performed adjusted for total livebirths
decreased (5.9% in 2000 vs. 3.2% in 2013) with 0.18% a year (95% CI: −0.21 to −0.15; p < 0.001). Following invasive
testing, a higher proportion of foetuses was diagnosed with T21 (1.6% in 2000 vs. 4.8% in 2013) with a signiﬁcant increase
of 0.22% a year (95% CI: 0.18–0.26; p< 0.001). The proportion of ToP subsequent to T21 diagnosis was on average 85.7%,
with no clear time trend. This resulted in a stable T21 livebirth prevalence of 13.6 per 10,000 livebirths (regression
coefﬁcient −0.025 (95% CI: −0.126 to 0.77; p= 0.60).
Introduction
Trisomy 21 (T21) or also called Down Syndrome (DS), is
the most common chromosomal disorder among liveborn
infants and is associated with intellectual disability and
other serious morbidity [1]. Studies have shown that T21
livebirth prevalence has been inﬂuenced mainly by two
trends with counteracting effects [2–7]. Firstly, in devel-
oped countries, a rise in maternal age increases the chance
of giving birth to a child with T21 [8]. For the Northern
Netherlands, the percentage of mothers aged > 35 years of
age has also increased from 12 to 17 percent in the period
1993–2004 [5]. Secondly, more precise and advanced
technologies for T21 screening during pregnancy have
become available and are being offered to pregnant women,
which may have changed T21 livebirth prevalence. In the
Netherlands, before 2007, prenatal screening with the First-
trimester Combined screening Test (FCT) was only
recommended for women older than 35 years. However,
women over 35 years could also opt for direct prenatal
diagnosis through an amniocentesis (AC) or chorion villous
sampling (CVS) [9]. A national program for prenatal
screening started in 2007 consisting of all pregnant women
receiving information about FCT in the ﬁrst trimester and
furthermore offering a structural anomaly scan in the second
trimester [10]. Risk assessment for trisomy 21, 13, and 18
with the FCT is based on maternal age, foetal nuchal
translucency thickness and concentrations of maternal
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serum-free β-human chorionic gonadotrophin and
pregnancy-associated plasma protein-A. If a woman
receives a “high-risk” FCT result ( ≥ 1:200) or abnormal
ultrasound ﬁndings are present, prenatal diagnostic testing
by CVS or AC is offered for follow-up. The purpose of
prenatal DS screening is to enable autonomous informed
decision making with regard to carrying pregnancy to term
or termination of pregnancy (ToP) [11, 12]. Studies have
shown that many women decline follow-up invasive testing,
sometimes due to the risk of miscarriage of 0.11–0.22%
[13–15]. Studies have shown that the vast majority
(85–95%) of the women that receive a foetal T21 diagnose
terminate their pregnancy [16]. It is unclear if actively
informing all pregnant women about prenatal screening
tests, starting around 2004, and resulting in a national
screening program in 2007, led to a change in livebirth
prevalence of T21. The aims of this study were to analyse
trends in factors that inﬂuence T21 livebirth prevalence and
to estimate livebirth prevalence of T21 in the Netherlands
for the period 2000–2013.
Subjects and methods
Model
In this study, we will estimate T21 livebirth number in the
Netherlands on the basis of a model with following vari-
ables: (1) number of total livebirths speciﬁed for maternal
age; (2) maternal age-speciﬁc T21 risk; and (3) number of
ToP in the case of T21. Livebirth prevalence is deﬁned as
the number of liveborn children with T21 per 10,000 live-
births (Fig. 1).
Data sets
In order to assess the numbers of the above-mentioned
variables and relevant trends of T21 in the Netherlands,
the following two data sets were combined: the Central
Bureau of Statistics (CBS) and the Working Party on
Prenatal Diagnosis and Therapy (WPDT). The CBS
collects and processes national data on a mandatory
basis, anonymously. The published data covers multiple
societal aspects of the Dutch population, including
numbers and speciﬁcs with regard to childbirth. In this
study, the total number of annual livebirths and maternal
age distribution (each year by age of mother in completed
years at the time of birth) were used. In the table of CBS,
some children have been included in a speciﬁc year in
which they were reported to the municipal administra-
tion, while they were born in the previous or next year.
Therefore, numbers are slightly different than the CBS
tables online [17]. The WPDT is part of the Dutch
Society for Clinical Genetics (VKGN) and the Dutch
Society for Obstetricians and Gynaecologists (NVOG).
Since 1991, the WPDT collects the data in the Nether-
lands concerning prenatal T21 screening. The WPDT
annual report contains statistics on performed prenatal
diagnoses by AC or CVS, diagnosed T21 cases and the
number of T21 pregnancies terminated after diagnosis.
Different WPDT reports are circulating, we used the ﬁnal
versions [18]. This data set does not contain personal
information and therefore is not privacy-sensitive. The
Medical Ethical Committee of VU University Medical
Center stated that no permission needed to be granted
for this study in accordance with Dutch research
legislation (WMO).
Livebirth prevalence of T21 = (actual number of T21 livebirths / number of total livebirths) x 10 000 
Actual number of T21 livebirths = (Expected number of T21 livebirths) – (corrected number of ToP) 
Expected number of T21 livebirths = Sum of (Number of women in each age category x maternal age 
specific T21 risk) for all age categories* 
Corrected number of ToP = (AC_ToP  x 0.75) + (CVS_ToP x 0.68) 
AC_ToP= termination of pregnancy following positive amniocentesis. CVS_ToP = 
termination of pregnancy following positive chorionic villus sampling. 
Correction rate of natural foetal loss for women screened by amniocentesis was 25% 
(therefore survival to term 1-0.25=0.75) and foetal loss rate for women screened by CVS 
was 32% (therefore survival to term 1-0.32= 0.68)
* each year by age of mother at the time of birth, from 15 years till 60 years old 
Fig. 1 Model for estimating livebirth prevalence of T21. Correction
rates of natural foetal loss for women screened by amniocentesis was
25% (therefore survival to term 1−0.25= 0.75) and foetal loss rates
for women screened by CVS were approximately 32% (therefore
survival to term 1−0.32= 0.68)* each year by age of mother at the
time of birth, from 15 years till 60 years old. AC_ToP termination of
pregnancy following positive amniocentesis, CVS_ToP termination of
pregnancy following positive chorionic villus sampling
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Expected number of T21 livebirths
By multiplying the number of women that delivered a
liveborn child in each age category by the age-speciﬁc T21
risks, and summing that for all maternal age categories, the
annual number of expected T21 children could be esti-
mated. The maternal age-speciﬁc risks of T21 proposed by
Morris were used [19]. Compared to the other models, the
analysis of Morris et al is the most recent model and based
on the largest data set. Furthermore, data from Morris et al
provide some evidence to show that the risk does not
continue to increase exponentially for women over age 45
as previous estimates assume [20]. With the expected
number of T21 livebirths, it was possible to estimate the
“natural prevalence”. The natural prevalence is the number
of children with T21 that would have been born in the
absence of prenatal screening and selective abortion per
10,000 livebirths.
Actual number of T21 livebirths
Next, the expected number of T21 livebirths is corrected for
the effect of prenatal testing and subsequent termination of
pregnancies. In 2011 and 2013, the WPDT annual reports
contained no information on the number of ToPs of the
centre in Nijmegen. We have estimated this number by
assuming that, in Nijmegen, the proportion of ToP (sepa-
rately for AC and CVS) was similar to that in the other
centres [21]. Still, the number of induced abortions does not
result in an equivalent reduction in the number of T21
livebirths due to the risk of natural foetal loss. Many of
these induced abortions would not have survived to term
and would not have been diagnosed, as miscarriages are
generally not karyotyped. The risk of natural foetal loss for
T21 varies between 19 and 44%, and depends on maternal
age and gestational age at prenatal testing [22]. Since our
data set on ToPs, information of maternal age was partially
missing, overall estimates of foetal loss for women of any
age were used. The correction factors of natural foetal loss
that we used for women screened by AC was 25% and for
women screened by CVS 32%. These factors are based on a
study of Savva et al. where foetal loss at different maternal
ages were estimated by survival analysis using follow-up of
5177 prenatally diagnosed cases [23]. The impact of pre-
natal screening is deﬁned as the difference between the
natural livebirth prevalence and actual livebirth prevalence,
divided by the natural livebirth prevalence.
Statistical analyses
Linear regression analyses were used to analyse time trends
in mean maternal age, the impact of prenatal screening and
T21 livebirths prevalence. Χ2 tests were used to investigate
whether the proportions of invasive tests, positive T21
diagnoses and ToP subsequent T21 diagnoses were differ-
ent between the period before (2000–2006) and after
(2007–2013) the implementation of the national screening
program. A p-value< 0.05 (two sided) was considered to be
statistically signiﬁcant. All statistical analyses were per-
formed using IBM SPSS 20.0.
Results
All livebirths in the Netherlands recorded by CBS are
included in the period 2000–2013 (N= 2 641 447). The
total number of annual livebirths decreased from 206,619
births in 2000 to 171,426 births in 2013.
Maternal age
The mean maternal age has slightly increased since 2000
from 30.2 years to 30.5 years in 2013 (Fig. 2), leading to a
signiﬁcant increasing trend of 0.014 year (95% CI:
0.001–0.027; p= 0.04). Because maternal age is reported as
a discrete variable (age last birthday) in the CBS tables, one
could add 6 months on top of the mean maternal age from
30.7 years in 2000 to 31.0 years in 2013. The gradual
increase of mean maternal age would seem to have stopped
in around 2006. The proportion of mothers aged ≥ 36 years
has increased from 12.2% in 2000 to 16.6% in 2009, to
gradually decrease afterwards to 15.2% in 2013 (Fig. 3).
Invasive tests
During the period 2000–2013, a total of 127 077 of invasive
tests were performed. Expressed as proportion of the total
livebirths, the number of invasive tests has steadily
decreased with 0.18% a year (95% CI: −0.21 to −0.15),
from 5.9% in 2000 to 3.2% in 2013 (p< 0.001).The pro-
portion of invasive tests decreased from 5.4% before to
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Fig. 2 Mean maternal age in the Netherlands, 2000–2013
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4.2% after implementation of the national screening pro-
gram in 2007 (p< 0.001). In 2000, advanced maternal age
was the main reason for invasive testing (73%), in 2013 this
was reduced till 28%. In contrast to the decreasing trend of
invasive tests performed, the proportion of positive T21
diagnoses from these tests has increased from 1.6% in 2000
to 4.8% in 2013, with a signiﬁcant increase of 0.22% a year
(95% CI 0.18 to 0.26; p< 0.001). The proportion of pre-
natal diagnosis after invasive tests increased from 2.1%
before to 3,6% after 2007 (p< 0.001). The proportion of
ToP subsequent to T21 diagnosis was on average 85.7%,
ﬂuctuating between 79.3% and 93.9%, with no clear time
trend (p= 0.11). Also no signiﬁcant change in proportion of
ToP was found before and after 2007 (p= 0.08). After T21
diagnosis by AC, the pregnancy was terminated less often
compared to CVS, with a range 73.6% till 93.6% and 83.6%
till 96,4%, respectively (Table 1). The impact of prenatal
screening increased with 29.2% in 2000 till 40.8% in 2013
and showed a signiﬁcant time trend of 0.86% a year (95%
CI: 0.32 to 1.40; p< 0.001).
Livebirth prevalence of T21
An integration of these data resulted in an estimated live-
birth prevalence of T21 that remained quite stable, ranging
from 12.4 to 14.7 per 10,000. The mean livebirth pre-
valence of T21 for the period of 2000–2013 was 13.6 per
10,000 livebirths (Fig. 4). No signiﬁcant trend in mean
livebirth prevalence of T21 over the years 2000–2013
(regression coefﬁcient −0.025 (95% CI: −0.13 to 0.77; p=
0.60) was found. A decline of the total number of livebirths
resulted in a decrease in the absolute number of livebirths
with T21 from 284 to 227 (Table 2).
Discussion
In this study, we found a stable livebirth prevalence of T21
in the Netherlands of 13.6 per 10,000 livebirths from 2000
to 2013. The effect of actively informing all pregnant
women about prenatal screening tests, starting around 2004,
and resulting in a national screening program in 2007, has
not led to a decrease in livebirth prevalence of T21, as
estimated by our model.
Model The model described in this study was based on
maternal age and maternal age-speciﬁc T21 risk factors [19,
20]. Using maternal age-speciﬁc risk factors to estimate
expected T21 pregnancies is a method used internationally,
as no large differences have been found when compared to
the empirical data. Especially for time trends, no systematic
differences are to be expected [24–26]. De Graaf et al.
(2011) used a similar model to estimate the livebirth pre-
valence of T21 in the Netherlands. They validated the
results using empirical data of postnatal T21 diagnoses.
Birth numbers estimated by the theoretical model were 4%
lower, resembling a mean difference of 0.5 per 10 000
births lower, compared with empirical data [6]. Although
there was a slight underestimation of birth prevalence, the
differences between both methods were small and the time
trends in birth prevalence were similar.
Trends in factors
First, advancing maternal age is a known risk factor for
T21. In the Netherlands, maternal age slightly increased till
around 2006; however, it did not rise any further. The
proportion of mothers aged ≥36 years has increased from
2000 to 2009, but gradually decreased till 2013. Further-
more, a decreasing trend in the number of performed pre-
natal invasive tests is present. Before 2007 FCT was already
being used in pilot studies and women older than 35 years
already had direct access to invasive testing. After intro-
duction of the FCT and the structural anomaly scan prenatal
diagnostic testing was used more effective, meaning mainly
women identiﬁed as having a high risk for T21 based on
FCT or based on ultrasound anomalies made use of prenatal
invasive tests [27, 28]. Because screening tests are more
precise than using age criterion a lower proportion of
women underwent invasive testing for maternal age criter-
ion alone [10].
The increase in the proportion of positive T21 diagnoses
through diagnostic testing from 2000 to 2013 can be
explained by a more accurate risk assessment for pregnant
women, as only high-risk women are referred for con-
ﬁrmation by invasive testing [28, 29]. Furthermore there is a
slight improvement to the test performance of the FCT [30].
The proportion of induced abortions subsequent to T21
diagnosis was on average 85.7%, ﬂuctuating between 79.3
and 93.9%, with no clear time trend. More prenatal diag-
noses of T21 in combination with a stable ToP rate after a
prenatal diagnosis counterbalanced the increase of the nat-
ural livebirth prevalence by increasing maternal age
(Fig. 4). In other words, the impact of prenatal testing
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increased. The decision for ToP is a difﬁcult one to take and
an emotional challenge inﬂuenced by many personal, social,
cultural and psychological factors [16, 31]. In general, the
proportion of pregnancy terminations in the Netherlands is
the lowest of all Western countries, being around 8.5–9 per
1000 [32, 33]. This can be explained by the fact that norms
and values of society with regard to childbirth and termi-
nation has considerable inﬂuence on the decision to termi-
nate a pregnancy. In the Netherlands, contraception and
communication concerning sexual activities and the poten-
tial consequences are readily available for young women.
Furthermore, the natural character of pregnancy is highly
valued; pregnancy and delivery are generally considered as
non-medical events that one should not ‘unnecessarily’
interfere with [34].
Livebirth prevalence of T21
The estimated livebirth prevalence remained stable during
2000–2013. The introduction of the nationwide screening
program in the Netherlands did not lead to a sharp decline
around 2007 but this can be explained by the fact that FCT
was already being used in pilot studies before 2007 and
women older than 35 years already had direct access to
invasive testing. Another breaking point in livebirth pre-
valence could have been 2004. Before 2004 physicians
were not allowed to actively inform pregnant women about
screening, unless there was a preceding medical reason (for
instance maternal age or a previous child with a trisomy in
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Fig. 4 Predicted livebirth prevalence of T21 in the Netherlands,
2000–2013. Natural prevalence: without prenatal diagnosis and ter-
mination of pregnancy. Actual prevalence: with prenatal diagnosis and
termination of pregnancy
Table 2 Estimated livebirth
prevalence of T21 in the
Netherlands, 2000–2013
Year Total
livebirths
Expected
number of
T21
livebirths
Natural
livebirth
prevalence
of T21 per
10 000
AC_ToP CVS_ToP Actual
number of
T21
livebirths
Impact of
prenatal
screening
(%)
Livebirth
prevalence
of T21 per
10 000
2000 206 619 401 19.4 99 63 284 29.2 13.7
2001 202 603 405 20.0 83 75 292 28.0 14.4
2002 202 083 410 20.3 107 77 277 32.3 13.7
2003 200 297 416 20.8 117 100 260 37.4 13.0
2004 194 007 413 21.3 118 108 251 39.2 12.9
2005 187 910 407 21.7 80 104 276 32.1 14.7
2006 185 057 407 22.0 99 107 260 36.1 14.0
2007 181 336 405 22.3 92 125 251 38.0 13.8
2008 184 634 414 22.4 111 141 235 43.3 12.7
2009 185 158 418 22.6 118 123 246 41.2 13.3
2010 184 325 418 22.7 125 141 228 45.4 12.4
2011 180 020 407 22.6 99 114 255 37.3 14.2
2012 175 972 395 22.4 78 127 250 36.7 14.2
2013 171 426 384 22.4 93 128 227 40.8 13.3
Actual number of T21 livebirths= expected number of T21 livebirths− ((AC_ToP× 0.75)+ (CVS_ToP×
0.68))
Impact of screening (%)= (expected number of T21 livebirths− actual number of T21 livebirths) / expected
number of T21 livebirths
The correction factor for natural foetal loss for women screened by AC was 25% and CVS was 32%
T21 trisomy 21, AC_ToP termination of pregnancy subsequent positive amniocentesis, CVS_ToP
termination of pregnancy subsequent positive chorionic villus sampling
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the family). Since 2004, this was allowed which already
caused an increase in the uptake of prenatal screening tests
before 2007. However, no decline of livebirth prevalence
was found in 2004. The reason for a stable livebirth pre-
valence may be the fact that FCT uptake remained relatively
low (27%) compared to other European countries. It has
been shown that the uptake of prenatal testing is strongly
associated with the screening policy of a certain country [4,
35]. Screening uptake in the Netherlands may have been
inﬂuenced by the additional costs for T21 screening (€160)
compared to the standard antenatal care. Furthermore, there
is a public debate that precedes the implementation of the
T21 screening program, and the ‘right not to know’ and
respect for autonomous choice in the Netherlands [35]. A
different aspect may be the way midwives are counselling
pregnant women by focussing on relationship building and
health education, instead of informed decision making [36].
Bakker et al. analysed 820 questionnaires of women in the
Netherlands and the main reason for the low uptake of the
FCT was the relatively positive attitude towards DS and a
negative attitude towards TOP [37].
Reported data about T21 livebirth prevalence over the
last decades vary. For 2003, Weijerman et al. (2008)
reported a T21 prevalence of 16 per 10,000 livebirths [38],
while European Registration of Congenital Anomalies
(EUROCAT) concluded that T21 livebirth prevalence was
15 per 10,000 [39]. De Graaf et al. (2011) reported a pre-
valence of 11 per 10,000 livebirths in the early 1990s,
increasing to around 14 per 10,000 in 2007 [6]. Van
Gameren-Oosterom et al. (2012) concluded that the pro-
portion of T21 livebirths did not change during the period
1997–2007, with a mean prevalence of 14.5 per 10,000
births, 85% of which were livebirths [40]. This would
correspond to 12.3 per 10,000 livebirths. Recently, a cohort
study performed in the Northern Netherlands showed a total
prevalence of T21 of 23.3 per 10,000 births with 57%
livebirths in 2005–2006 and 56% in 2007–2012. This
would correspond to 13.2 per 10,000 livebirths [41]. The
reason for this slightly lower livebirth prevalence may be
the lower maternal age of the northern region of the Neth-
erlands compared to other regions [42]. A very recent study
by de Graaf et al. (2017) shows an increase of livebirth
prevalence from 11.6 per 10,000 in 1991 to a peak of 15.9
per 10,000 in 2002, followed by a slight decrease to 13.4
per 10,000 in 2013 (and 11.1 per 10,000 in 2015). Livebirth
estimates were based on numbers of postnatal T21 diag-
noses by cytogenetic centers and non-ToP numbers of
prenatal T21 diagnoses in WPDT reports. A correction had
to be made for livebirths and natural foetal loss in the non-
ToP category. De Graaf et al. modelled this correction in
two different ways. In both scenarios, there is a decreasing
livebirth prevalence after 2002. Estimates for 2014 and
2015, as regards the percentage of livebirths after a prenatal
diagnoses, were based on trend data from preceding years
[39]. It is surprising that de Graaf et al. ﬁnd a decreasing
trend also only for 2000 till 2013 and in the current study no
such trend was found. How can this difference in trend be
explained? First of all, the major limitation of these studies
is that the estimates of number of livebirths with T21 are not
completely based on actual counts. Present study is based
on a model using maternal age in general population, and
the data on ToP and natural loss in case of T21. The study
of de Graaf et al. models the number of livebirths with T21
in the number of reported non-ToPs. However, the current
model of Morris et al. leads to an estimation of livebirth
prevalence of on average 13.6 per 10,000 for the period
2000–2013, which is the same as found in the recent study
of de Graaf et al. for the same period of time. There was no
speciﬁc maternal age information, so the overall estimates
of natural foetal loss rate were used. However, over-
estimates of the foetal loss rate in younger mothers will
cause the weight of prenatally diagnosed cases to be too
low, which will lead to an overestimation of the actual
livebirth prevalence. Also, underestimation of the foetal loss
rate in older mothers will cause the weight of prenatally
diagnosed cases to be too high, which will lead to an
underestimation of the expected livebirth prevalence.
Finally, it may be possible that we found a stable livebirth
prevalence by chance because the 95% conﬁdence intervals
in such a model approach as used in the current study on an
annual basis are fairly large.
Because NIPT became available in 2013 in neighbouring
countries, overestimation of T21 livebirth prevalence is
possible. In the Netherlands, NIPT became available only
for women at increased risk for T21 after the FCT in April
2014. This led to about 3000–3600 Dutch women crossing
the border to undergo NIPT at their own costs [43]. The
numbers of T21 cases in this low-risk population is prob-
ably too small to affect our estimates, since perhaps almost
all T21 diagnoses are conﬁrmed using invasive diagnostic
testing in the Netherlands and thereby registered in the
database of the WPDT currently used. [44]
In the Netherlands, there is no national registry system
for T21. EUROCAT is a regional system of Northern
Netherlands and does not cover the whole country. The
Perinatal Registry Netherlands foundation (PRN) contains
records of all infants born from 16 weeks of gestation under
the care of a midwife at home or in a hospital, as well as
those born under the care of an obstetrician in a hospital
within the ﬁrst 28 days of life. Similar to EUROCAT, this
registration is done on a voluntary basis. In addition, no
conﬁrmatory genetic test is needed for the registration of
DS. As a result from the voluntary basis, it is likely that
underestimation is present. A national registry system that
collects complete data of childbirth and T21 diagnosis is
needed to ensure baseline data.
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Conclusion and future research
This study showed a stable livebirth prevalence of T21 with
a mean of 13.6 per 10,000 in the Netherlands during the
period 2000–2013. The national screening program in 2007
for all pregnant women seems to have had limited impact on
the livebirth prevalence of T21.
Qualitative studies could provide more insights into
whether and how parents make their reproductive decisions.
Since April 2017 non-invasive prenatal testing (NIPT) is
introduced in the Netherlands as a ﬁrst-tier screening test as
alternative for the FCT. The media has generated intense
debate about DS and the NIPT screening test. The question
remains if the livebirth prevalence of T21 will change. In our
opinion a national registry is needed to ensure baseline data.
Currently, the data on the number of postnatal diagnoses can
be derived from the cytogenetic centers. However, individual
centres have to be approached. The recommendation is to
collect these data on annual basis in a national registry. Data
on prenatal diagnoses and reported ToPs can be derived from
the WPDT reports. However, accurate reporting is required
to avoid that multiple versions of WPDT reports are circu-
lating. Furthermore in the non-ToPs category, a distinction
could be made in the categories ‘livebirths’, ‘natural loss/still
births’, and ‘unknown outcomes’. A national register could
contain further maternal and neonatal information as well.
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